HROW Trading Analysis - 11/16/2026 04:21 PM — TRU-SENTIMENT

HROW (Harrow Inc. Common Stock) at $29.12. True Sentiment Bullish, delta 40-60 call 96% / put 4%, call $58,370 vs put $2,140. RSI 54.6.

TRU-SENTIMENT · DeltaNeutral

HROW Trading Analysis - 11/16/2026 04:21 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

HROW (Harrow Inc. Common Stock) at $29.12. True Sentiment Bullish, delta 40-60 call 96% / put 4%, call $58,370 vs put $2,140. RSI 54.6.

Symbol
HROW
Price
$29.12
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-11-16 16:21:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From HROW_options_20261116 data: Sentiment Bullish. Call dollar vol $58,370 (96.5%), Put $2,140 (3.5%). Contracts: 79 call / 6 put. Total analyzed 404, true filter 6 (1.5%).

Call Volume: $58,370 (96.5%) Put Volume: $2,140 (3.5%) Total: $60,510

Pure directional conviction strongly bullish via calls. Divergence: technicals show no clear direction (MACD neg, below SMA50) while options flow bullish – matches spread recommendation "divergence detected".

Note: Options flow shows heavy call buying at Delta 40-60 filter (96.5% call dollar vol).

Key Statistics: HROW

$29.00 -3.40%
52-Week Range
$25.76 - $54.85
Market Cap
$1.09B
P/E (TTM)
39.60
PEG Ratio
N/A
Beta
1.71
Next Earnings
N/A
Avg Volume
$466,326
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)39.60
EPS (trailing 12 mo)$-0.76
Market cap$1.09B
Shares outstanding37.5M

Dividend

Dividend yield0.00%

Risk & range

Beta1.71
52-week low$25.76
52-week high$54.85
Historical volatility60.8%

Ownership & trading

Institutional ownership34.6%
Average daily volume0.7M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

The following items are based on general knowledge of HROW (Harrow Health) and are provided as context only, separate from the data-driven analysis below.

  • Harrow Health reported Q3 2026 results showing continued revenue growth in its ophthalmic pharmaceutical segment, with management citing expanded commercial footprint.
  • Company announced a new FDA-approved compounded medication launch in late October 2026, viewed as a potential catalyst for forward earnings.
  • Biotech/specialty pharma sector saw renewed interest in November 2026 after a broader market risk-on move, lifting small-cap names like HROW.
  • No confirmed near-term earnings date post November 13, but historical fiscal year-end is December 1, suggesting upcoming financial disclosures.
  • Headlines of product expansion align with the sharp November 10 volume spike (1.9M shares) and subsequent options bullishness in the embedded data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for HROW:

  • Trailing P/E is 39.60 with trailing EPS of -0.76 (negative earnings). No forward P/E, PEG, or revenue data supplied.
  • Market cap is $1,088,457,000 with 37,533,000 shares outstanding; dividend yield 0.00% (no dividend).
  • Beta is 1.71 (high relative volatility vs market); 52-week range $25.76 to $54.85, price well below midpoint.
  • Institutional ownership 34.61%; average volume 699,000; historical volatility 60.77% (elevated).
  • Key concerns: Negative EPS, no margin/ROE/debt-to-equity/free cash flow data; no analyst target or consensus provided.
  • Fundamentals (negative earnings, rich P/E) diverge from options sentiment (bullish) and recent price rebound off 52-week low.

Current Market Position

From embedded data: Daily close on 2026-11-13 was $30.02. Minute bars show 2026-11-13 open $28.37, high $31.10, low $28.31, close $30.02 (volume 628,622). Last minute bar 2026-11-16 15:50 close $29.12 (day high $29.27, low $29.04). Intraday 11-16 shows mild drift lower from $29.27 to $29.12 on thinning volume (<9k/bar). Recent price action: drop to $25.76 (11-06), rebound to $33.68 (11-10), settle ~$28–30.

Support
$26.42 (BB lower)
Resistance
$30.54 (BB upper)
30d Low
$25.76
30d High
$33.68

Technical Analysis

Technical Indicators

Current Price
$30.02
SMA 5
$29.00
SMA 20
$28.48
SMA 50
$30.77
RSI 14
54.61
MACD
-0.54
Signal
-0.43
Hist
-0.11
BB Mid
$28.48
BB Up
$30.54
BB Lo
$26.42
ATR 14
$1.94

Price ($30.02) is above SMA 5 ($29.00) and SMA 20 ($28.48) but below SMA 50 ($30.77) – no golden cross, slight bearish alignment vs 50-day. RSI 54.61 = neutral momentum. MACD -0.54 below signal -0.43, histogram -0.11 (bearish mild). Bollinger: price inside bands, mid $28.48, upper $30.54 (price near upper). 30-day range $25.76–$33.68; price at ~57% of range. ATR $1.94 shows elevated daily swing.

True Sentiment Analysis (Delta 40-60 Options)

From HROW_options_20261116 data: Sentiment Bullish. Call dollar vol $58,370 (96.5%), Put $2,140 (3.5%). Contracts: 79 call / 6 put. Total analyzed 404, true filter 6 (1.5%).

Call Volume: $58,370 (96.5%) Put Volume: $2,140 (3.5%) Total: $60,510

Pure directional conviction strongly bullish via calls. Divergence: technicals show no clear direction (MACD neg, below SMA50) while options flow bullish – matches spread recommendation "divergence detected".

Note: Options flow shows heavy call buying at Delta 40-60 filter (96.5% call dollar vol).

Key Price Levels (Observational Only)

Support
$28.48 (SMA20/BB mid)
Support
$26.42 (BB lower)
Resistance
$30.54 (BB upper)
Resistance
$30.77 (SMA50)
Resistance
$33.68 (30d high)

Interactive charts load with JavaScript. This text is the crawlable summary.